Drug intelligence / Profile preview

pyriproxyfen + alphacypermethrin

Development stage
Unknown
Lead developer
Disease Control Technologies
Modality
Small Molecules
Administration
Topical
01

Overview

pyriproxyfen + alphacypermethrin is a combination insecticide and insect growth regulator (IGR) primarily used in public health and veterinary medicine. Alphacypermethrin is a synthetic Type II pyrethroid that acts as a potent neurotoxin by modulating voltage-gated sodium channels in insect nerve cells. It prevents the channels from closing, leading to prolonged sodium influx, repetitive nerve firing, paralysis, and rapid death (knockdown effect). Pyriproxyfen is a juvenile hormone analog that mimics natural insect hormones to disrupt the life cycle. It prevents larvae from maturing into adults and significantly reduces the reproductive capacity of adult insects by inducing sterility in females. This dual-action approach is particularly effective for managing insecticide resistance in mosquito populations, such as those carrying malaria, and for controlling ectoparasites in livestock and pets.

Brand names
Royal Guard
Other names
alpha-cypermethrin + pyriproxyfenalphacypermethrin/pyriproxyfen mixture
02

Targets

NaV (Voltage-gated sodium channels)MET (Mesenchymal-epithelial transition factor receptor)

Beyond the preview

Go deeper on pyriproxyfen + alphacypermethrin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on pyriproxyfen + alphacypermethrin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call